PointState Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

PointState Capital’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-30,020	Closed	-$18.2M	–	166
2021 Q3	$18.2M	Buy	30,020 +7,020	+31%	+$4.36M	0.3%	61
2021 Q2	$12.8M	Buy	+23,000	New	+$11.7M	0.22%	71
2021 Q1	–	Sell	-35,733	Closed	-$17.3M	–	163
2020 Q4	$17.3M	Buy	35,733 +19,313	+118%	+$10.4M	0.32%	62
2020 Q3	$9.19M	Sell	16,420 -25,927	-61%	-$15.7M	0.24%	59
2020 Q2	$26.4M	Buy	42,347 +32,804	+344%	+$18.6M	0.8%	29
2020 Q1	$4.66M	Sell	9,543 -125,025	-93%	-$51.6M	0.23%	38
2019 Q4	$50.5M	Buy	134,568 +120,368	+848%	+$40.5M	0.92%	33
2019 Q3	$3.94M	Buy	+14,200	New	+$4.2M	0.11%	72
2017 Q3	–	Sell	-159,220	Closed	-$78.2M	–	169
2017 Q2	$78.2M	Buy	+159,220	New	+$69.7M	0.85%	38

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

PointState Capital's REGN Position: Q4 2021 in Review

PointState Capital sold out of Regeneron Pharmaceuticals (REGN) in Q4 2021, closing a stake of 30,020 shares — an estimated $18.2M sold.

PointState Capital first reported a position in REGN in Q2 2017 and held it in 9 quarters. The position peaked at $78.2M in Q2 2017. 1,078 funds tracked by Wall St. Rank hold REGN as of Q4 2021.

PointState Capital reported no remaining Regeneron Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
PointState Capital sold 30,020 Regeneron Pharmaceuticals shares in Q4 2021, an estimated $18.2M.
PointState Capital first reported a position in Regeneron Pharmaceuticals in Q2 2017 and held it in 9 quarters.
PointState Capital's Regeneron Pharmaceuticals position peaked at $78.2M in Q2 2017.
1,078 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2021.

Based on PointState Capital's 13F filing for Q4 2021, filed 11 Feb 2022.